Development of New Preventive and Therapeutic Vaccines for Tuberculosis

키워드

참고문헌 (85)

1. Paulson T, "Epidemiology: a mortal foe", Nature, 502, pp.S2~S3 (2013)[DOI]
2. Global Tuberculosis Report 2016, "World Health Organization", World Health Organization, ~ (2016)
3. Havlir DV, "Opportunities and challenges for HIV care in overlapping HIV and TB epidemics", JAMA, 300, pp.423~430 (2008)[DOI]
4. Lonnroth K, "Tuberculosis control and elimination 2010-50: cure, care, and social development", Lancet, 375, pp.1814~1829 (2010)[DOI]
5. Rehm J, "The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review", BMC Public Health, 9, pp.450~ (2009)[DOI]
6. Vynnycky E, "The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection", Epidemiol Infect, 119, pp.183~201 (1997)[DOI]
7. Mazurek GH, "Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection", JAMA, 286, pp.1740~1747 (2001)[DOI]
8. Kolloli A, "Host-directed therapeutic strategies for tuberculosis", Front Med (Lausanne), 4, pp.171~ (2017)[DOI]
9. Pontali E, "Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence", Eur Respir J, 47, pp.394~402 (2016)[DOI]
10. Agyeman AA, "Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis", Ann Clin Microbiol Antimicrob, 15, pp.41~ (2016)[DOI]
11. Bruns H, "Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages", J Immunol, 189, pp.4069~4078 (2012)[DOI]
12. Napier RJ, "Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity", PLoS Pathog, 11, pp.e1004770~ (2015)[DOI]
13. Napier RJ, "Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis", Cell Host Microbe, 10, pp.475~485 (2011)[DOI]
14. Singhal A, "Metformin as adjunct antituberculosis therapy", Sci Transl Med, 6, pp.263ra159~ (2014)[DOI]
15. Verreck FA, "Variable BCG efficacy in rhesus populations: pulmonary BCG provides protection where standard intra-dermal vaccination fails", Tuberculosis (Edinb), 104, pp.46~57 (2017)[DOI]
16. Brewer TF, "Preventing tuberculosis with Bacillus Calmette-Guerin vaccine: a meta-analysis of the literature", Clin Infect Dis, 31, pp.S64~S67 (2000)[DOI]
17. Mangtani P, "Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials", Clin Infect Dis, 58, pp.470~480 (2014)[DOI]
18. Grode L, "Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial", Vaccine, 31, pp.1340~1348 (2013)[DOI]
19. Nieuwenhuizen NE, "The recombinant Bacille Calmette-Guerin vaccine VPM1002: ready for clinical efficacy testing", Front Immunol, 8, pp.1147~ (2017)[DOI]
20. Geoffroy C, "Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes", Infect Immun, 55, pp.1641~1646 (1987)
21. Grode L, "Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis Bacille Calmette-Guerin mutants that secrete listeriolysin", J Clin Invest, 115, pp.2472~2479 (2005)[DOI]
22. Decatur AL, "A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity", Science, 290, pp.992~995 (2000)[DOI]
23. Moliva JI, "Prospects in Mycobacterium bovis Bacille Calmette et Guerin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?", Vaccine, 33, pp.5035~5041 (2015)[DOI]
24. Fletcher HA, "TB vaccine development and the end TB strategy: importance and current status", Trans R Soc Trop Med Hyg, 110, pp.212~218 (2016)[DOI]
25. Loxton AG, "Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa", Clin Vaccine Immunol, 24, pp.e00439~16 (2017)
26. Fletcher HA, "Sleeping beauty and the story of the Bacille Calmette-Guerin vaccine", MBio, 7, pp.e01370~16 (2016)
27. Kaufmann SH, "Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review", Lancet Respir Med, 2, pp.301~320 (2014)[DOI]
28. Lee JS, "Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain", Cell Host Microbe, 3, pp.97~103 (2008)[DOI]
29. Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group, "Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014", Vaccine, 33, pp.3047~3055 (2015)[DOI]
30. Arbues A, "Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials", Vaccine, 31, pp.4867~4873 (2013)[DOI]
31. Mearns H, "H1:IC31 vaccination is safe and induces long-lived TNF-alpha+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: a randomized trial", Vaccine, 35, pp.132~141 (2017)[DOI]
32. Reither K, "Safety and immunogenicity of H1", IC31(R), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells, PLoS One, pp.2014, 9[DOI]
33. van Dissel JT, "A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human", Vaccine, 32, pp.7098~7107 (2014)[DOI]
34. Luabeya AK, "First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults", Vaccine, 33, pp.4130~4140 (2015)[DOI]
35. Billeskov R, "The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity", PLoS One, 7, pp.e39909~ (2012)[DOI]
36. Skeiky YA, "Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen", Vaccine, 28, pp.1084~1093 (2010)[DOI]
37. Cha SB, "Pulmonary immunity and durable protection induced by the ID93", GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K, 2016, pp.34, 2179~2187
38. Coler RN, "Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment", J Infect Dis, 207, pp.1242~1252 (2013)[DOI]
39. Dockrell HM, "Towards new TB vaccines: what are the challenges?", Pathog Dis, 74, pp.ftw016~ (2016)[DOI]
40. Tameris MD, "Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial", Lancet, 381, pp.1021~1028 (2013)[DOI]
41. van Zyl-Smit RN, "Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial", Am J Respir Crit Care Med, 195, pp.1171~1180 (2017)[DOI]
42. Xing Z, "Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis", PLoS One, 4, pp.e5856~ (2009)[DOI]
43. Smaill F, "A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity", Sci Transl Med, 5, pp.205ra134~ (2013)[DOI]
44. Mendez-Samperio P, "Global efforts in the development of vaccines for tuberculosis: requirements for improved vaccines against Mycobacterium tuberculosis", Scand J Immunol, 84, pp.204~210 (2016)[DOI]
45. von Reyn CF, "Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine", AIDS, 24, pp.675~685 (2010)[DOI]
46. Butov DA, "Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB", J Immune Based Ther Vaccines, 9, pp.3~ (2011)[DOI]
47. Gupta A, "Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model", Vaccine, 30, pp.6198~6209 (2012)[DOI]
48. He L, "Flow cytometry: an efficient method for antigenicity measurement and particle characterization on an adjuvanted vaccine candidate H4-IC31 for tuberculosis", J Immunol Methods, 452, pp.39~45 (2018)[DOI]
49. Neeland MR, "The lymphatic immune response induced by the adjuvant AS01: a comparison of intramuscular and subcutaneous immunization routes", J Immunol, 197, pp.2704~2714 (2016)[DOI]
50. Detienne S, "Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01", Sci Rep, 6, pp.39475~ (2016)[DOI]
51. Gillard P, "Safety and immunogenicity of the M72", AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study, 2016, pp.100, 118~127
52. Rose F, "Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: a quality-by-design approach", J Control Release, 210, pp.48~57 (2015)[DOI]
53. Velmurugan K, "Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells", PLoS Pathog, 3, pp.e110~ (2007)[DOI]
54. Gengenbacher M, "Deletion of nuoG from the vaccine candidate Mycobacterium bovis BCG deltaurec:hly improves protection against tuberculosis", MBio, 7, pp.e00679~16 (2016)
55. Moguche AO, "Antigen availability shapes T cell differentiation and function during tuberculosis", Cell Host Microbe, 21, pp.695~706 (2017)[DOI]
56. Brandt L, "ESAT-6 subunit vaccination against Mycobacterium tuberculosis", Infect Immun, 68, pp.791~795 (2000)[DOI]
57. Esparza-Gonzalez SC, "Recombinant adenovirus delivery of calreticulin-ESAT-6 produces an antigen-specific immune response but no protection against a Mycobacterium tuberculosis challenge", Scand J Immunol, 75, pp.259~265 (2012)[DOI]
58. Gurunathan S, "DNA vaccines: immunology, application, and optimization*", Annu Rev Immunol, 18, pp.927~974 (2000)[DOI]
59. Feng G, "Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection", PLoS One, 8, pp.e61135~ (2013)[DOI]
60. Liang Y, "Ag85A", ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice, 2016, pp.14, 1146~1152
61. Seo H, "IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours", Nat Commun, 8, pp.15776~ (2017)[DOI]
62. Chung Y, "CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo", Cancer Res, 66, pp.6843~6850 (2006)[DOI]
63. Kim YJ, "alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity", Int J Cancer, 122, pp.2774~2783 (2008)[DOI]
64. Hong C, "CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection", J Immunol, 177, pp.6747~6757 (2006)[DOI]
65. Chung Y, "An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity", Blood, 110, pp.2013~2019 (2007)[DOI]
66. Hong C, "Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells", Cancer Res, 69, pp.4301~4308 (2009)[DOI]
67. de Jonge MI, "ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity", J Bacteriol, 189, pp.6028~6034 (2007)[DOI]
68. Seghatoleslam A, "Macrophage immune response suppression by recombinant Mycobacterium tuberculosis antigens, the ESAT-6, CFP-10, and ESAT-6", CFP-10 fusion proteins, 2016, pp.41, 296~304
69. Francis RJ, "Mycobacterium tuberculosis ESAT-6 is a leukocidin causing Ca2+ influx, necrosis and neutrophil extracellular trap formation", Cell Death Dis, 5, pp.e1474~ (2014)[DOI]
70. Welin A, "Human macrophages infected with a high burden of ESAT-6-expressing M. tuberculosis undergo caspase-1- and cathepsin B-independent necrosis", PLoS One, 6, pp.e20302~ (2011)[DOI]
71. Romagnoli A, "ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells", Autophagy, 8, pp.1357~1370 (2012)[DOI]
72. Dong H, "ESAT6 inhibits autophagy flux and promotes BCG proliferation through MTOR", Biochem Biophys Res Commun, 477, pp.195~201 (2016)[DOI]
73. Hsu T, "The primary mechanism of attenuation of Bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue", Proc Natl Acad Sci U S A, 100, pp.12420~12425 (2003)[DOI]
74. Smith J, "Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole", Infect Immun, 76, pp.5478~5487 (2008)[DOI]
75. Peng X, "Mechanism of ESAT-6 membrane interaction and its roles in pathogenesis of Mycobacterium tuberculosis", Toxicon, 116, pp.29~34 (2016)[DOI]
76. Sreejit G, "The ESAT-6 protein of Mycobacterium tuberculosis interacts with beta-2-microglobulin (beta2M) affecting antigen presentation function of macrophage", PLoS Pathog, 10, pp.e1004446~ (2014)[DOI]
77. Sengupta S, "Mycobacterium tuberculosis EsxL inhibits MHC-II expression by promoting hypermethylation in class-II transactivator loci in macrophages", J Biol Chem, 292, pp.6855~6868 (2017)[DOI]
78. Watson RO, "The cytosolic sensor cGAS detects Mycobacterium tuberculosis DNA to induce type I interferons and activate autophagy", Cell Host Microbe, 17, pp.811~819 (2015)[DOI]
79. Watson RO, "tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway", Cell, 150, pp.803~815 (2012)[DOI]
80. Collins AC, "Cyclic GMP-AMP synthase is an innate immune DNA sensor for Mycobacterium tuberculosis", Cell Host Microbe, 17, pp.820~828 (2015)[DOI]
81. Wassermann R, "Mycobacterium tuberculosis differentially activates cGAS- and inflammasome-dependent intracellular immune responses through ESX-1", Cell Host Microbe, 17, pp.799~810 (2015)[DOI]
82. Koster S, "Mycobacterium tuberculosis is protected from NADPH oxidase and LC3-associated phagocytosis by the LCP protein CpsA", Proc Natl Acad Sci U S A, 114, pp.E8711~E8720 (2017)[DOI]
83. McElvania Tekippe E, "Granuloma formation and host defense in chronic Mycobacterium tuberculosis infection requires PYCARD", ASC but not NLRP3 or caspase-1, 2010, pp.5, e12320~
84. Saiga H, "Critical role of AIM2 in Mycobacterium tuberculosis infection", Int Immunol, 24, pp.637~644 (2012)[DOI]
85. Ruhwald M, "Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6", Sci Rep, 7, pp.45969~ (2017)[DOI]

관련 논문AI추천